[go: up one dir, main page]

MX2023001492A - Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. - Google Patents

Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.

Info

Publication number
MX2023001492A
MX2023001492A MX2023001492A MX2023001492A MX2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A MX 2023001492 A MX2023001492 A MX 2023001492A
Authority
MX
Mexico
Prior art keywords
fatigue
subject
inflammatory cytokines
mediated disease
complement mediated
Prior art date
Application number
MX2023001492A
Other languages
English (en)
Inventor
ARIAS Jaime MORALES
William E Hobbs
Michael J Storek
Parija S Patel
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2023001492A publication Critical patent/MX2023001492A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/306—Chronic fatigue syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar enfermedades mediadas por el complemento, como la enfermedad de las aglutininas frías (CAD) y afecciones asociadas, como la fatiga, utilizando anticuerpos anti-C1s como sutimlimab, en donde dichos métodos implican la medición de un nivel de IL-6 y/o IL-10.
MX2023001492A 2020-08-06 2021-08-05 Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. MX2023001492A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062243P 2020-08-06 2020-08-06
PCT/US2021/044761 WO2022031978A1 (en) 2020-08-06 2021-08-05 Inflammatory cytokines and fatigue in subject with a complement mediated disease

Publications (1)

Publication Number Publication Date
MX2023001492A true MX2023001492A (es) 2023-03-08

Family

ID=77750323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001492A MX2023001492A (es) 2020-08-06 2021-08-05 Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.

Country Status (11)

Country Link
US (1) US20230357433A1 (es)
EP (1) EP4193153A1 (es)
JP (1) JP2023536904A (es)
KR (1) KR20230044312A (es)
CN (1) CN116724236A (es)
AU (1) AU2021320870A1 (es)
BR (1) BR112023001942A2 (es)
CA (1) CA3187866A1 (es)
IL (1) IL300376A (es)
MX (1) MX2023001492A (es)
WO (1) WO2022031978A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124553A1 (en) 2012-10-25 2014-05-01 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2018071676A1 (en) 2016-10-12 2018-04-19 Bioverativ Usa Inc. Anti-c1s antibodies and methods of use thereof
CN117241828A (zh) * 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
US20240117021A1 (en) * 2022-06-15 2024-04-11 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
WO2023250507A1 (en) * 2022-06-24 2023-12-28 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2014186622A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
IL256424B2 (en) * 2015-06-26 2024-09-01 Bioverativ Usa Inc Methods of treating autoimmune and alloimmune disorders
EP3503903A4 (en) * 2016-08-25 2020-03-25 California Institute of Technology ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
WO2018071676A1 (en) * 2016-10-12 2018-04-19 Bioverativ Usa Inc. Anti-c1s antibodies and methods of use thereof
EP3596121A1 (en) 2017-03-14 2020-01-22 Bioverativ USA Inc. Methods for treating complement-mediated diseases and disorders
BR112020018357A2 (pt) * 2018-04-13 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Anticorpos de componente anticomplemento e métodos de uso
US20200140533A1 (en) * 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury

Also Published As

Publication number Publication date
CN116724236A (zh) 2023-09-08
BR112023001942A2 (pt) 2023-02-28
KR20230044312A (ko) 2023-04-03
CA3187866A1 (en) 2022-02-10
IL300376A (en) 2023-04-01
EP4193153A1 (en) 2023-06-14
AU2021320870A1 (en) 2023-04-06
JP2023536904A (ja) 2023-08-30
WO2022031978A1 (en) 2022-02-10
US20230357433A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MX2023001492A (es) Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2022010224A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2023009831A (es) Metodos y sistemas para mejorar la condicion dermica.
PH12022550167A1 (en) High concentration anti-c5 formulations
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
HK1250238A1 (zh) 抗angptl8抗体及其用途
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
MY205096A (en) Anti-lag-3 antibodies
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
WO2016154623A3 (en) Anti-cd133 monoclonal antibodies and related compositions and methods
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
EP4349864A3 (en) Oncostatin m receptor antigen binding proteins
ZA202203254B (en) Immunocytokine comprising heterodimeric protein complex based on il-15/il-15rα
BR112017023867A2 (pt) métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
MY203247A (en) Anti-trkb monoclonal antibodies and methods of use
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
MX2025012892A (es) Anticuerpos que se unen a ox40l y metodos de uso
ZA202305072B (en) Cd1a antibodies and uses thereof
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof